Lene Weber Vestermark

1.7k total citations · 1 hit paper
28 papers, 1.2k citations indexed

About

Lene Weber Vestermark is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lene Weber Vestermark has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 14 papers in Epidemiology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lene Weber Vestermark's work include Neuroendocrine Tumor Research Advances (13 papers), Lung Cancer Research Studies (13 papers) and Colorectal Cancer Treatments and Studies (8 papers). Lene Weber Vestermark is often cited by papers focused on Neuroendocrine Tumor Research Advances (13 papers), Lung Cancer Research Studies (13 papers) and Colorectal Cancer Treatments and Studies (8 papers). Lene Weber Vestermark collaborates with scholars based in Denmark, Sweden and Norway. Lene Weber Vestermark's co-authors include Halfdan Sørbye, Seppo W. Langer, Eva Tiensuu Janson, Henning Grønbæk, Ulrich Knigge, Pia Österlund, Birgitte Federspiel, Staffan Welin, J Assmus and Eva Hofsli and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and British Journal of Cancer.

In The Last Decade

Lene Weber Vestermark

28 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

2012 714 citations Halfdan Sørbye, Staffan Welin et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lene Weber Vestermark Denmark	13	1.1k	997	667	119	88	28	1.2k
Letizia Boninsegna Italy	25	2.3k 2.2×	2.3k 2.3×	1.4k 2.0×	62 0.5×	219 2.5×	31	2.5k
Michail Shafir United States	10	204 0.2×	182 0.2×	92 0.1×	50 0.4×	166 1.9×	29	446
Laura Gilardi Italy	11	309 0.3×	195 0.2×	148 0.2×	86 0.7×	102 1.2×	36	514
Nazzarena Bigiani Italy	8	302 0.3×	220 0.2×	73 0.1×	134 1.1×	115 1.3×	9	422
Maria Cecilia Mengoli Italy	13	258 0.2×	124 0.1×	96 0.1×	319 2.7×	92 1.0×	56	587
Terence N. Moore United States	9	251 0.2×	212 0.2×	51 0.1×	151 1.3×	120 1.4×	14	446
David Schreiber United States	10	214 0.2×	172 0.2×	31 0.0×	144 1.2×	101 1.1×	23	388
Hyun Y. Pak United States	12	208 0.2×	196 0.2×	136 0.2×	122 1.0×	70 0.8×	18	455
DP Deakin United Kingdom	7	549 0.5×	50 0.1×	80 0.1×	88 0.7×	38 0.4×	9	714
J Rosai Cyprus	8	380 0.4×	82 0.1×	71 0.1×	82 0.7×	64 0.7×	10	567

Countries citing papers authored by Lene Weber Vestermark

Since Specialization

Citations

This map shows the geographic impact of Lene Weber Vestermark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lene Weber Vestermark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lene Weber Vestermark more than expected).

Fields of papers citing papers by Lene Weber Vestermark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lene Weber Vestermark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lene Weber Vestermark. The network helps show where Lene Weber Vestermark may publish in the future.

Co-authorship network of co-authors of Lene Weber Vestermark

This figure shows the co-authorship network connecting the top 25 collaborators of Lene Weber Vestermark. A scholar is included among the top collaborators of Lene Weber Vestermark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lene Weber Vestermark. Lene Weber Vestermark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sørbye, Halfdan, Geir Olav Hjortland, Lene Weber Vestermark, et al.. (2025). Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. British Journal of Cancer. 133(3). 316–324. 8 indexed citations

Langer, Seppo W., Anna Sundlöv, Lene Weber Vestermark, et al.. (2023). Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. British Journal of Cancer. 129(12). 1930–1939. 11 indexed citations

Sørbye, Halfdan, Aurel Perren, Inger Marie Bowitz Lothe, et al.. (2023). Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine Related Cancer. 30(10). 6 indexed citations

Pommergaard, Hans‐Christian, Halfdan Sørbye, Birgitte Federspiel, et al.. (2021). Surgery of the primary tumour in 201 patients with high‐grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine‐non‐neuroendocrine neoplasms. Journal of Neuroendocrinology. 33(5). e12967–e12967. 32 indexed citations

Langer, Seppo W., Birgitte Federspiel, Geir Olav Hjortland, et al.. (2020). PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS ONE. 15(12). e0243900–e0243900. 14 indexed citations

Perren, Aurel, Jean‐Yves Scoazec, Laura H. Tang, et al.. (2020). A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology. 111(9). 883–894. 73 indexed citations

Grönberg, Malin, Seppo W. Langer, Morten Ladekarl, et al.. (2018). Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology. 35(4). 47–47. 10 indexed citations

Grönberg, Malin, Birgitte Federspiel, Jean‐Yves Scoazec, et al.. (2017). Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS ONE. 12(11). e0187667–e0187667. 27 indexed citations

Knigge, Ulrich, Eva Tiensuu Janson, Lene Weber Vestermark, et al.. (2017). Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology. 43(9). 1682–1689. 40 indexed citations

10.

Winther, Stine Brændegaard, Camilla Qvortrup, Lene Weber Vestermark, et al.. (2016). Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncologica. 55(7). 881–885. 7 indexed citations

11.

Pfeiffer, Per, et al.. (2013). Single Institution Experience with S-1 (Teysuno) in Danish Patients with Gastro-Intestinal Cancer. Annals of Oncology. 24. iv74–iv74. 2 indexed citations

12.

Sørbye, Halfdan, Staffan Welin, Seppo W. Langer, et al.. (2012). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology. 24(1). 152–160. 714 indexed citations breakdown →

13.

Nielsen, Dorte, Lene Weber Vestermark, Per Pfeiffer, et al.. (2012). Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer. The Breast. 21(4). 556–561. 14 indexed citations

14.

Vestermark, Lene Weber, et al.. (2012). High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): A phase I trial. Acta Oncologica. 51(3). 311–317. 12 indexed citations

15.

Sørbye, Halfdan, Staffan Welin, Seppo W. Langer, et al.. (2012). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study.. Journal of Clinical Oncology. 30(15_suppl). 4015–4015. 10 indexed citations

16.

Bjerregaard, Jon Kroll, Tine Plato Hansen, Karin de Stricker, et al.. (2011). Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer. 14(3). 219–225. 16 indexed citations

17.

Andersen, Maria, et al.. (2010). Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta Oncologica. 49(8). 1246–1252. 10 indexed citations

18.

Jensen, Lars Henrik, Henrik Harling, Mikael Jensen, et al.. (2009). Clinical outcome in 520 consecutive Danish rectal cancer patients treated with short course preoperative radiotherapy. European Journal of Surgical Oncology. 36(3). 237–243. 8 indexed citations

19.

Vestermark, Lene Weber, Camilla Qvortrup, Flemming Hansen, et al.. (2008). Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC). Acta Oncologica. 47(3). 428–433. 20 indexed citations

20.

Vestermark, Lene Weber, et al.. (2008). A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncologica. 47(8). 1526–1530. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact